| Prev. close | $6.70 | |
| Model | Value | Upside |
|---|---|---|
| Chepakovich | $2.49 | -63% |
| Graham-Dodd | $0.00 | -100% |
| Graham | $0.00 | -100% |
| Previous Close | $6.70 | ||
| Valuation Method | Value | Potential | |
|---|---|---|---|
| Chepakovich Model | $2.49 | -63% | recalculate |
| Graham-Dodd | $0.00 | -100% | recalculate |
| Graham Formula | $0.00 | -100% | recalculate |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.